Long-Term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands

被引:24
|
作者
Janssen-Heijnen, Maryska L. [1 ,2 ]
van Steenbergen, Liza N. [2 ]
Steyerberg, Ewout [3 ]
Visser, Otto [4 ]
De Ruysscher, Dirk K. [5 ]
Groen, Harry J. [6 ]
机构
[1] VieCuri Med Ctr, Dept Clin Epidemiol, NL-5900 BX Venlo, Netherlands
[2] Eindhoven Canc Registry, Comprehens Canc Ctr S, Eindhoven, Netherlands
[3] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands
[4] Comprehens Canc Ctr Netherlands, Dept Registrat & Res, Amsterdam, Netherlands
[5] Maastricht Univ Med Ctr, Dept Radiat Oncol, Maastro Clin, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, NL-9713 AV Groningen, Netherlands
关键词
Conditional survival; Non-small cell lung cancer; Long-term survivors; Excess mortality; UP-TO-DATE; CONDITIONAL SURVIVAL; PATIENT SURVIVAL; PERIOD ANALYSIS; ALTERNATIVE APPROACH; CARCINOMA; RATES; EPIDEMIOLOGY; PROGNOSIS; LOBECTOMY;
D O I
10.1097/JTO.0b013e318241f80b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Most patients diagnosed with non-small cell lung cancer (NSCLC) die within the first few years after diagnosis. However, only little is known about those who have survived these first years. We aimed to study conditional 5-year relative survival rates for NSCLC patients during long-term follow-up. Methods: All 12,148 patients aged 45 to 74 years diagnosed with stage I-III NSCLC between 1989 and 2008 in the Netherlands were derived from the Netherlands Cancer Registry. Conditional 5-year relative survival was calculated for every additional year survived up to 15 years. Results: Conditional 5-year relative survival rapidly improved with every year survived up to 4 to 5 years after diagnosis. However, a significant excess mortality of 20 to 40% remained. Conditional 5-year relative survival for those aged 45 to 59 years did not exceed 80% for survivors with stage I or II disease and remained just more than 70% for those with stage III disease. For those aged 60 to 74 years, these proportions were 70%, 65%, and 60%, respectively. Conclusions: A significant excess mortality remains in lung cancer after years which may be explained by excess risk of death due to smoking-related comorbidity in these patients. Caregivers should use this information for planning optimal cancer surveillance and informing cancer survivors about their actual prognosis.
引用
收藏
页码:496 / 502
页数:7
相关论文
共 50 条
  • [1] Long-term Excess Mortality for Survivors of Non-small Cell Lung Cancer in the Netherlands
    Janssen-Heijnen, M.
    van Steenbergen, L.
    Steyerberg, E.
    Visser, O.
    De Ruysscher, D.
    Groen, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S599 - S599
  • [2] Long-term survivors in stage IV non-small cell lung cancer
    Okamoto, T
    Maruyama, R
    Shoji, F
    Asoh, H
    Ikeda, J
    Miyamoto, T
    Nakamura, T
    Miyake, T
    Ichinose, Y
    [J]. LUNG CANCER, 2005, 47 (01) : 85 - 91
  • [3] Quality of Life in Japanese Long-Term Survivors of Non-Small Cell Lung Cancer
    Fujimori, Maiko
    Uchitomi, Yosuke
    [J]. PSYCHO-ONCOLOGY, 2014, 23 : 356 - 357
  • [4] Long-term survivors after chemotherapy in advanced non-small cell lung cancer
    Satoh, Hiroaki
    Ishikawa, Hiroichi
    Ohara, Gen
    Kagohashi, Katsunori
    Kurishima, Koichi
    Ohtsuka, Morio
    Hizawa, Nobuyuki
    [J]. ANTICANCER RESEARCH, 2007, 27 (6C) : 4457 - 4460
  • [5] Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands
    Janssen-Heijnen, M. L. G.
    van Steenbergen, L. N.
    Voogd, A. C.
    Tjan-Heijnen, V. C. G.
    Nijhuis, P. H.
    Poortmans, P. M.
    Coebergh, J. W. W.
    van Spronsen, D. J.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (01) : 64 - 68
  • [6] Extended pneumonectomy for non-small cell lung cancer: Morbidity, mortality, and long-term results
    Borri, Alessandro
    Leo, Francesco
    Veronesi, Giulia
    Solli, Piergiorgio
    Galetta, Domenico
    Gasparri, Roberto
    Petrella, Francesco
    Scanagatta, Paolo
    Radice, Davide
    Spaggiari, Lorenzo
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 134 (05): : 1266 - 1272
  • [7] Long-term survivors of more than 5 years in advanced non-small cell lung cancer
    Kaira, Kyoichi
    Takahashi, Toshiaki
    Murakami, Haruyasu
    Tsuya, Asuka
    Nakamura, Yukiko
    Naito, Tateaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    [J]. LUNG CANCER, 2010, 67 (01) : 120 - 123
  • [8] Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
    Nadal, Ernest
    Massuti, Bartomeu
    Domine, Manuel
    Garcia-Campelo, Rosario
    Cobo, Manuel
    Felip, Enriqueta
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) : 341 - 352
  • [9] Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
    Ernest Nadal
    Bartomeu Massuti
    Manuel Dómine
    Rosario García-Campelo
    Manuel Cobo
    Enriqueta Felip
    [J]. Cancer Immunology, Immunotherapy, 2019, 68 : 341 - 352
  • [10] Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer
    Yildizeli, Bedrettin
    Fadel, Elie
    Mussot, Sacha
    Fabre, Dominique
    Chataigner, Olivier
    Dartevelle, Philippe G.
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2007, 31 (01) : 95 - 102